Navigation Links
Viral Enzyme Recruited in Fight Against Ear Infection

Parents might one day give their children a weekly treatment with a nasal spray of virus enzymes to prevent them from getting a severe middle //ear infection, based on results of a study. Such a treatment would kill the disease-causing bacteria without the use of antibiotics, thereby avoiding the problem of antibiotic resistance.

Middle ear infection, also called acute otitis media, is an inflammation of the middle ear space that can cause pain, fever, irritability, lack of appetite and vomiting. The middle ear is the space just before the eardrum. About half of all children carry the bacteria that cause acute otitis media, which migrate from the nose and throat to the middle ear after an initial influenza virus infection paves the way.

The investigators based their treatment on the ability of viruses called phages to break out of bacteria they infect by using a special enzyme to destroy the cell walls. Phages infect bacteria in a way that is similar to how viruses infect animal cells. Once inside, the virus hijacks the cell’s biochemical machinery and forces it to make many copies of the virus. After the new crop of viruses is made, a viral enzyme breaks apart the infected bacterial cell wall and allows the new viruses to escape and infect additional cells.

The success of the new treatment, which uses a phage enzyme to kill the bacteria that cause acute otitis media, suggests that the strategy could significantly reduce the incidence of the disease in the United States, where more than 24 million cases are diagnosed yearly. Even though the current pneumonia vaccine protects against Streptococcus pneumoniae—the bacteria that cause acute otitis media—this ear infection remains the leading cause of doctor visits and antibiotic prescriptions among preschool-aged children. In the current study, the researchers treated mice with the enzyme lysine, the same enzyme used by phages to break out of S. pneumoniae.

In addition t o its promise for preventing acute otitis media, the virus enzyme treatment also appears to hold promise for preventing the secondary pneumonia caused when a person infected with S. pneumoniae is subsequently infected with the influenza virus.

“Secondary bacterial infections cause much of the sickness and about 25 percent of all deaths during the flu season, and 50 to 95 percent of deaths during pandemics of influenza,” said Jonathan McCullers, M.D., associate member in the Infectious Diseases department at St. Jude. “Eliminating these secondary infections could dramatically reduce the sickness and death rates among susceptible populations such as infants and the elderly.” This new approach might also offer some protection if the avian influenza virus, H5N1, sparks a pandemic among humans, he added. McCullers is first author of the “PLoS” paper.

The investigators demonstrated in mice infected with S. pneumoniae that lysin can eliminate these bacteria from the ear. The team conducted their study in mice developed at St. Jude that represented the first mouse model in which acute otitis media develops in a similar way that it develops the disease in children. The mice were treated by purified lysin that was prepared in the laboratory of Vincent A. Fischetti, Ph.D., a professor and co-head of the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University. He was assisted by Jutta M. Loeffler, postdoctoral associate. Fischetti is senior author of the PLoS paper.

The researchers developed a mouse model of acute otitis media by first establishing colonization of S. pneumoniae in the noses of mice. Scientists then infected some of the mice with influenza virus and mock-infected others with a virus-free solution. Although all the mice carried the bacteria in their noses, none of the mock-infected mice developed acute otitis media, while 63 percent of mice receiving influenza virus developed this middle ear infection .

In the second part of the study, the team treated bacteria-colonized mice twice, four hours apart, with either lysin or a mock treatment of fluid. The lysin treatment was 100 percent effective in preventing acute otitis media in the 10 treated mice while 80 percent of mice receiving the fake treatment developed the ear infection.

“The nasal spray may eventually be used weekly during the flu season to keep the person free of Streptococcus pneumoniae or after someone is infected with the flu virus, Fischetti said. “This might truly be a case in which an ounce of prevention would be worth a pound of cure.”

Source-ANS
SRM
'"/>




Related medicine news :

1. Viral encephalitis can cause more damage than already known
2. Gene-Nanoparticle Gene Transfer Is Better Than Viral Vector Transfer System
3. Therapeutic Genes Transferred By Viral Vector Through T Cell Masking
4. Possible Viral Cause Of Kawasaki Disease Identified
5. Viral Infection At Birth Leads To Cerebral Palsy.
6. African Viral Fever Hits Two TN Districts
7. Viral Haemorrhagic Septicaemia Attack On Farmed Trout
8. Spread of New Viral Fever Reported in Five States
9. Viral Epidemic In Gujarat
10. Kerala Tourism Affected by Viral Fever Outbreak
11. A New Viral Infection Causes Death Of A Baby In Britain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and thank ... Every day, two kidneys filter about 120 to 150 quarts of blood. Put another ... regulating fluid levels and blood pressure, supporting bone health and promoting red blood cell ...
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... program owned and organized by HMP Communications Holdings, LLC, today announced that ... within its nationwide network of wound centers interested in becoming Certified Wound Specialist ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 backers ... crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, LLC, ... excited to be operating on U.S. shores, where most of our initial crowdfunding backers ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... YORK , March 23, 2017 ... (NASDAQ: MYL), Allergan PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: ... These Generic Drugs stocks are part of the Healthcare sector, ... 22 nd , 2017, with the NYSE Health Care Index ... companies in the S&P 500 also were up nearly 0.1% ...
(Date:3/23/2017)... Global Colposcope Market by Manufacturers, Countries, Type and Application, Forecast ... in North America , Europe ... , Middle East and ... regions, type and application. ... Browse 190 Tables and Figures, 19 Major Company Profiles, spread ...
(Date:3/23/2017)... 23, 2017 During the ... Brussels , My UV Patch, La ... habits into life-saving ones, was awarded the Diamond ... in 2016, the "Nudging for Good" Award aims ... desirable for people to change behaviour and adopt ...
Breaking Medicine Technology: